The Foundation for the National Institutes of Health (FNIH) employs a range of innovative technologies and methodologies to advance biomedical research and improve patient care. One notable initiative is the Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) project, which focuses on evaluating noninvasive blood and imaging tests to detect and assess liver disease. This project highlights the use of ultrasound elastography, a technique that measures liver stiffness through low-frequency vibrations, providing a safer and less invasive alternative to traditional liver biopsies. The FNIH's research aims to enhance the understanding of liver disease progression and facilitate clinical trials for new treatments by establishing reliable diagnostic tools.

Additionally, the FNIH fosters public-private partnerships that connect leading researchers with various stakeholders, including biopharma companies and regulatory agencies. This collaborative approach is exemplified in programs like the Accelerating Medicines Partnership® (AMP®), which aims to accelerate the development of new therapies and diagnostics. By leveraging cutting-edge technologies and fostering interdisciplinary collaboration, the FNIH is committed to addressing complex health challenges and promoting breakthroughs that can lead to improved health outcomes for diverse populations.

United States

Foundation for the Institutes of Health (FNIH)

Foundation for the Institutes of Health (FNIH)

Company Details